Bone homeostasis is regulated by bone formation and resorption, with most antiosteoporosis drugs, such as bisphosphonates, inhibiting bone resorption. "Bisphosphonates inhibit bone resorption, but do ...

Increased osteoclastic bone resorption is almost always responsible for hypercalcemia, regardless of tumor type or mediator; after hydration, the use of bone-resorption inhibitors (most commonly ...

A major challenge is evaluating the risk for ONJ in patients receiving bone resorption inhibitors. Among patients with osteoporosis on these treatments, ONJ incidence ranges from 0.001% to 0.050%.

In bone resorption, ... Cite this: Markers of Bone Metabolism in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer - Medscape - May 01, 2009. Abstract and Introduction; ...

Bone metastases, which occur in the course of many cancers, are also often caused by bone resorption processes. ... So far, drugs are available that inhibit bone resorption by osteoclasts.

Benefits of Bone-Modifying Agents Confirmed in Breast Cancer – Reduced skeletal morbidity, but overall clinical outcomes still up in the air by Wayne Kuznar , Contributing Writer September 6, 2016 ...

"Osteoporotic patients treated with [bone resorption inhibitors] may be at risk of glucose intolerance." The researchers include Mathieu Ferron, Columbia University, New York, NY; ...

The key to understanding cancer treatment–associated bone loss in women is estrogen. Estrogen has a protective effect on bone via multiple mechanisms; the net effect is to stimulate new bone formation ...

The strength of bone is determined by its material composition and structure. 2 Bone must be stiff and able to resist deformation, thereby making loading possible. Bone must also be flexible: it ...